Company research
Azitra, Inc.
CIK 1701478Updated Sep 29, 2026
SecurityAZTR · NYSE_AMERICAN · equity
Name history
Azitra Inc · through Jan 4, 2024
AZTR price & chart
Loading TradingView…
AMEX:AZTR on TradingView ↗About the company
We are an early-stage clinical biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. We have built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics. The platform is augmented by an artificial intelligence and machine learning technology that analyzes, predicts and helps screen our library of strains for drug-like molecules. The platform also utilizes a licensed genetic engineering technology, which can enable the transformation of previously genetically intractable strains. Our initial focus is on the development of genetically engineered strains of Staphylococcus epidermidis, or S. epidermidis, which we consider to be an optimal therapeutic candidate species for engineering of dermatologic therapies. The particular species demonstrates a number of well-described properties in the skin. As of the date of this prospectus, we have identified among our microbial library over 60 distinct bacterial species that we believe are capable of being engineered to…
In the news
Azitra Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American News provided by Azitra, Inc. Dec 17, 2025, 16:10 ET Share this article Share to X Share this article Share to X BRANFORD, Conn. , Dec. 17, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clin ↗
Recent filings
Entry into a Material Definitive Agreement
Items 1.01, 9.01
424B5 filing
Regulation FD Disclosure
Items 7.01, 9.01
Other Events
Items 8.01, 9.01
SCHEDULE 13G filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 5,025,386Source | 7,358,802Source | 5,115,486Source | 7,167,443Source |
| Property, Plant and Equipment, NetUSD | 548,591Source | 653,957Source | 710,075Source | 846,958Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 316,673Source | 246,420Source | 210,881Source | 219,567Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 2,068,083Source | 4,554,719Source | 1,795,989Source | 3,492,656Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 912Source | — | — | — |
| Assets, CurrentUSD | 3,019,327Source | 5,228,290Source | 2,535,579Source | 4,135,883Source |
| Operating Lease, Right-of-Use AssetUSD | 404,444Source | 527,393Source | 828,960Source | 1,116,697Source |
| Other Assets, NoncurrentUSD | 47,402Source | 46,941Source | — | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 1,224,156Source | 1,660,504Source | 2,202,340Source | 9,733,211Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | — | — |
| Common Stock, Value, IssuedUSD | 1,074Source | 763Source | 1,210Source | 104Source |
| Additional Paid in CapitalUSD | 72,321,352Source | 63,263,360Source | 51,510,269Source | 1,054,138Source |
| Retained Earnings (Accumulated Deficit)USD | -68,521,196Source | -57,565,825Source | -48,598,333Source | -37,314,552Source |
| Stockholders' Equity Attributable to ParentUSD | 3,801,230Source | 5,698,298Source | 2,913,146Source | -36,260,310Source |
| Liabilities and EquityUSD | 5,025,386Source | 7,358,802Source | 5,115,486Source | 7,167,443Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 1,067,966Source | 1,375,857Source | 1,603,195Source | 2,222,032Source |
| Operating Lease, Liability, CurrentUSD | 255,776Source | 255,177Source | 307,655Source | 287,384Source |
| Accounts Payable, CurrentUSD | 399,356Source | 490,255Source | 897,272Source | 784,687Source |
| Operating Lease, Liability, NoncurrentUSD | 156,190Source | 274,161Source | 537,523Source | 840,896Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 197,484Source | 602,787Source | 383,668Source | 993,961Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 138,069Source | 131,188Source | 129,653Source | 125,885Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 62,744Source | 245,053Source | 151,505Source | 184,465Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 679Source | -98,022Source | -84,565Source | 21,953Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | 0Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -11,224,125Source | -10,183,740Source | -7,362,375Source | -8,349,469Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -182,909Source | -379,246Source | -318,259Source | -336,761Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 24,213Source | 8,569Source | 26,544Source | 33,101Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 8,920,398Source | 13,321,716Source | 5,983,967Source | 4,134,624Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 2,068,083Source | 4,554,719Source | 1,795,989Source | 3,492,656Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 9,182Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 62,744Source | 245,053Source | — | — |
| Amortization of Intangible AssetsUSD | 13,712Source | 11,162Source | 7,643Source | 5,234Source |
| DepreciationUSD | 124,357Source | 120,026Source | 122,010Source | 120,651Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 0Source | 14,198Source | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -2,069Source | -4,859Source | -41,417Source | -7,923Source |
| General and Administrative ExpenseUSD | 6,130,657Source | 6,269,262Source | 4,493,332Source | 3,639,666Source |
| Goodwill and Intangible Asset ImpairmentUSD | 0Source | 0Source | 78,606Source | — |
| Goodwill, Impairment LossUSD | — | — | 78,606Source | — |
| Impairment of Intangible Assets (Excluding Goodwill)USD | 0Source | 442,793Source | 351,360Source | — |
| Impairment of Intangible Assets, Finite-livedUSD | 0Source | 442,793Source | — | — |
| Income Tax Expense (Benefit)USD | 8,319Source | 9,031Source | 17,308Source | — |
| InterestExpenseNonoperatingUSD | 7,587Source | 12,160Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -10,955,370Source | -8,967,492Source | -11,283,781Source | -10,680,366Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | -8,967,492Source | -12,639,128Source | -13,449,350Source |
| Nonoperating Income (Expense)USD | 19,614Source | 2,026,679Source | -3,650,078Source | -1,226,762Source |
| Operating ExpensesUSD | 10,966,665Source | 10,992,640Source | 8,302,395Source | 9,737,604Source |
| Operating Lease, ExpenseUSD | 323,182Source | 338,856Source | — | — |
| Other Nonoperating Income (Expense)USD | -43,389Source | 15,014Source | 89,886Source | -25,351Source |
| Proceeds from Issuance of Common StockUSD | 5,942,307Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | 0Source | 19,100Source | — | 1,510Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 0Source | 7,500Source | 686,000Source | 284,000Source |
| Operating Income (Loss)USD | -10,966,665Source | -10,985,140Source | -7,616,395Source | -9,453,604Source |
| Other Nonoperating Income (Expense)USD | -43,389Source | 15,014Source | 89,886Source | -25,351Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -10,947,051Source | -8,958,461Source | -11,266,473Source | -10,680,366Source |
| Income Tax Expense (Benefit)USD | 8,319Source | 9,031Source | 17,308Source | — |
| Net Income (Loss) Attributable to ParentUSD | -10,955,370Source | -8,967,492Source | -11,283,781Source | -10,680,366Source |
| Earnings Per Share, BasicUSD per share | -2.25Source | -2.37Source | -1.83Source | -12.74Source |
| Earnings Per Share, DilutedUSD per share | -2.25Source | -2.37Source | -1.83Source | -12.74Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 4,873,552Source | 3,784,482Source | 6,924,453Source | 1,055,399Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 4,873,552Source | 3,784,482Source | 6,924,453Source | 1,055,399Source |
| Interest Expense (non-operating)USD | 7,587Source | 12,160Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 13,712Source | 11,162Source | 7,643Source | 5,234Source |
| Current Income Tax Expense (Benefit)USD | 8,319Source | 9,031Source | 17,308Source | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 0Source | 14,198Source | — | — |
| General and Administrative ExpenseUSD | 6,130,657Source | 6,269,262Source | 4,493,332Source | 3,639,666Source |
| Goodwill, Impairment LossUSD | — | — | 78,606Source | — |
| Interest ExpenseUSD | — | — | 167,726Source | 251,891Source |
| Interest Income, OtherUSD | 70,209Source | 122,553Source | 1,577Source | 4,818Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | -8,967,492Source | -12,639,128Source | -13,449,350Source |
| Net Income (Loss) from Continuing Operations Available to Common Shareholders, BasicUSD | — | — | -12,639,128Source | -13,449,350Source |
| Nonoperating Income (Expense)USD | 19,614Source | 2,026,679Source | -3,650,078Source | -1,226,762Source |
| Operating ExpensesUSD | 10,966,665Source | 10,992,640Source | 8,302,395Source | 9,737,604Source |
| Operating Lease, ExpenseUSD | 323,182Source | 338,856Source | — | — |
| Other IncomeUSD | — | — | — | 65,849Source |
| Preferred Stock Dividends, Income Statement ImpactUSD | — | 0Source | 1,355,347Source | 2,768,984Source |
| Research and Development ExpenseUSD | 4,836,008Source | 4,723,378Source | 3,809,063Source | 6,097,938Source |
Offerings
Registration 333-296125
Registration 333-292049
Registration 333-289961
Registration 333-288766
Registration 333-286809
Filing attachments
ex99-1.htm · 8-K · 2026-09-08
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Azitra, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference BRANFORD, Conn. - September 8, 2026 - Azitra, Inc. (“Azitra” or the “Company”) (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, today announced that Travis Whitfill Ph. D., MPH, Azitra’s Co-founder and Chief Operating Officer, will…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-21
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards BRANFORD, Conn. - August 21, 2026 - Azitra, Inc. (“Azitra” or the “Company”) (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, today announced that it has received written notification from NYSE American LLC (“NYSE American”) confirming that…
Read attachment ↗ex99-1.htm · 8-K · 2026-07-15
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Azitra, Inc. Announces Breakthrough Repeat Dose and Anti-Wrinkle Ex Vivo Results for ATR-COSF Program, Demonstrating Increased Distribution and Elasticity ATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, filaggrin (“rHDfilaggrin”). This S. epidermis derived supernatant is in development as a high value cosmetic ingredient Ex vivo data successfully showed controlled distribution …
Read attachment ↗ex99-1.htm · 8-K · 2026-06-17
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond BRANFORD, Conn. - June 17, 2026 - Azitra, Inc. (“Azitra” or the “Company”) (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that Francisco Salva, Chief Executive Officer of Azitra, has issued a Letter to Shareholders detaili…
Read attachment ↗ex99-1.htm · 8-K · 2026-06-04
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Azitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting BRANFORD, Conn. - June 4, 2026 - Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced its 2026 Annual Meeting, originally scheduled for and convened on June 4, 2026, has been adjourned until June 15, 2026, at 11:00 a.m. Eastern Time, because the Com…
Read attachment ↗ex99-1.htm · 8-K · 2026-05-27
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Azitra Announces Intention to Adjourn Annual Meeting and Reconvene Annual Meeting BRANFORD, Conn. - May 27, 2026 - Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it intends to convene its upcoming 2026 annual meeting of stockholders (the “2026 Annual Meeting”) scheduled for June 4, 2026 at 11:00 a.m., Eastern Time, and then imm…
Read attachment ↗